Inhibition of cancer-cell migration by tetraspanin CD9-binding peptide

  • Chem Commun (Camb). 2021 May 18;57(40):4906-4909. doi: 10.1039/d1cc01295a.
Thanawat Suwatthanarak  1 ,  Masayoshi Tanaka  1 ,  Yoshitaka Miyamoto  2 ,  Kenji Miyado  2 ,  Mina Okochi  1
Affiliations
  • 1. Department of Chemical Science and Engineering, Tokyo Institute of Technology, 2-12-1, O-okayama, Meguro-ku, Tokyo 152-8552, Japan. [email protected].
  • 2. Department of Reproductive Biology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan.
PMID: 33870995 DOI: 10.1039/d1cc01295a
Abstract

A CD9-binding peptide (RSHRLRLH), screened from EWI-2, was characterized, and its effect on cellular migration and invasion was evaluated. As CD9 protein is overexpressed in Cancer cells and plays an important role in cellular migration, the CD9-binding peptide preferentially inhibited the migration of Cancer cells. Unlike conventional antiproliferative drugs, this CD9-binding peptide is promising as a novel precision antimigratory agent for Cancer therapeutics.

Products